Alluvi, previously BI 4744, represents a significant advance in obesity care. This dual stimulator targeting both GLP-1 and GIP targets demonstrates compelling effectiveness in patient trials, potentially surpassing https://alluvi-healthcare593813.p2blogs.com/41579599/alluvi-a-detailed-investigation-into-retatrutide-s-possibilities